N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma

References

• Neri A, Murphy J P, Cro P, Ferrero D, Tarella C, Baldini L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170: 1715–1725
   PubMed Web of Science ®Google Scholar
• Paquette R L, Berenson J, Lichtenstein A, McCormick F, Koeffler H P. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene 1990; 5: 1659–1663
   PubMed Web of Science ®Google Scholar
• Matozaki S, Nakagawa T, Nakao Y, Fujita T. RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J Med Sci 1991; 37: 35–45
   PubMedGoogle Scholar
• Portier M, Moles J P, Mazars G R, Jeanteur P, Bataille R, Klein B, et al. P53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7: 2539–2545
   PubMed Web of Science ®Google Scholar
• Liu P, Leong T, Quam L, Billadeau D, Kay N E, Greip P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trail. Blood 1996; 88: 2699–2706
   PubMed Web of Science ®Google Scholar
• Hallek M, Lelf P Bergsagel, Anderson K C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21
   PubMed Web of Science ®Google Scholar
• Tanaka K, Takechi M, Asaoku H, Dohy H, Kamada N. A high frequency of N-RAS oncogene mutations in multiple myeloma. Int J Hematol 1992; 56: 119–127
   PubMed Web of Science ®Google Scholar
• Berenson J R, Bergsagel P L, Munshi N. Initiation and maintenance of multiple myeloma. Semin Hematol 1999; 36: 9–13
   PubMed Web of Science ®Google Scholar
• Bezieau S, Devilder M C, Avet-Loiseau H, Mellerin M P, Puthier D, Pennarun E, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukaemia at diagnosis. Hum Mutat 2001; 18: 212–224
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Rothwell D G, Scarffe H, Norton J D. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma. Blood 2001; 98: 1555–1560
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, Johnsen H E, Dahl I MS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323
   PubMed Web of Science ®Google Scholar
• Billadeau D, Jelinek D F, Shan N, LeBien T W, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995; 55: 3640–3646
   PubMed Web of Science ®Google Scholar
• Duncan B B, Schmidt M I, Polansky C A. High mortality rates among Brazilian adult populations – an international comparison. Revista da Associação Médica Brasileira 1992; 38: 138–144
   PubMedGoogle Scholar
• Barlogie B, Shaughnessy J, Munshi N, Epstein J. Plasma cell myeloma. Hematology, M A Beutler, B S Lichtman, T J Coller, U Kipps. McGraw-Hill, New York, NY 2001; 1279–1304
   Google Scholar
• Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Saiki R K, Gelfand D H, Stoffel S, Scharf S J, Higuchi R, Horn G T, et al. Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 1988; 239: 487–491
   PubMed Web of Science ®Google Scholar
• Ahuja H G, Forti A, Bar-Eli M, Cline M J. The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75: 1684–1690
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles D M, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasia. Blood 1993; 81: 2708–2713
   PubMed Web of Science ®Google Scholar
• Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K, Aoki N. N-ras and p53 gene mutations are very rare events in multiple myeloma. Int J Hematol 1995; 62: 91–97
   PubMed Web of Science ®Google Scholar
• Byrne J L, Marshall C J. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br J Haematol 1998; 100: 256–264
   PubMed Web of Science ®Google Scholar
• Barbacid M. Ras gene. Ann Rev Biochem 1987; 56: 779–827
   PubMed Web of Science ®Google Scholar
• Radich J P, Kopecky K J, Willman C L, Weick J, Head D, Appelbaum F, et al. N-ras mutations in adult de novo acute myelogenous leukaemia: prevalence and clinical significance. Blood 1990; 76: 801–807
   PubMed Web of Science ®Google Scholar
• Ballerini P, Gaidano G, Gong J Z, Tassi V, Saglio G, Knowles D M, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993; 81: 166–176
   PubMed Web of Science ®Google Scholar
• Brose M S, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997–7000
   PubMed Web of Science ®Google Scholar
• Yuen S T, Davies H, Chan T L, Ho J W, Bignell G R, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451–6455
   PubMed Web of Science ®Google Scholar